Franchise Network Stagnation
Franchise count remained flat at 180-190 over 3 years after a failed experiment with non-medical franchise owners. Management pivoted to hospital growth but hasn't demonstrated franchise scaling capability.
VAIDYASANEAYURVEDLABORAT / Q4-FY26 / risks
Keep the risk register visible.
Vaidyasaneayurvedlaborat · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Care Plan Conversion Decline
Annual therapy conversions declined from 33,800 in FY25 to 28-29,000 in FY26. Analyst flagged this as concerning; management attributed to excluding smaller diet care plans but didn't provide consolidated conversion data.
H2 EBITDA Margin Compression
H2 EBITDA (excluding other income) was ₹6.80 Cr on revenue of ₹56.96 Cr (~11.9% margin), down from ₹8.56 Cr in H2 FY25. Management cited ₹50-60 lakh/month call center costs but did not quantify total H2 margin impact.
Pending Insurance Empanelment and Regulatory Approvals
Three hospitals awaiting CGHS portal activation despite NABH approval; Nagpur hospital expansion awaiting government permissions. Delays could impact FY27 bed capacity targets.